Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer
Chao H Huang, Stephen K Williamson, Prakash Neupane, Sarah A Taylor, Ace Allen, Nora J Smart, Adelina M Uypeckcuat, Sarah Spencer, Jo Wick, Holly Smith, Peter J Van Veldhuizen, Karen Kelly, Chao H Huang, Stephen K Williamson, Prakash Neupane, Sarah A Taylor, Ace Allen, Nora J Smart, Adelina M Uypeckcuat, Sarah Spencer, Jo Wick, Holly Smith, Peter J Van Veldhuizen, Karen Kelly
Abstract
Background: Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation, and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets IGF-1R. Pemetrexed (P) has higher activity in non-squamous lung cancer (NSQL). We initiated a randomized phase II trial to test the combination of P and Cisplatin (C) ± D in NSQL.
Methods: Eligibility criteria were untreated NSQL stage IV, ECOG 0 or 1, measurable disease, adequate renal, hepatic and hematologic function, and no other intercurrent illness. P at 500 mg/m(2) and C at 75 mg/m(2) IV were given every 3 weeks. D was given at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle in the experimental group. The patients had a radiographic assessment after every two cycles and were treated for a maximum of six cycles if there was a response or stable disease. The primary objective of the study was to compare the clinical response rates of PC vs. PC + D.
Results: From 1/2009 to 2/2011, the study accrued 26 subjects: 16 male and 10 female, with a median age of 59; 14 were treated with PC and 12 were treated with PC + D. We observed two partial responses (PR), seven stable disease (SD), three progressive disease (PD), and two not evaluable (NE) in the PC arm. In comparison, for the PC + D arm, there were three PR, four SD, four PD, and one NE. The hematologic toxicity was similar in both groups. There was higher incidence of hyperglycemia in the experimental group; four cases with grade 3 and one case with grade 4.
Conclusion: PC + D had a similar response rate compared to PC, with a higher rate of hyperglycemia. Identification of responders using predictive markers would be key to continuing the study of D in NSQL.
Trial registration: NCT00799240, clinicaltrials.gov.
Keywords: IGF-1R; dalotuzumab; metastatic; non-squamous cell lung cancer; pemetrexed; treatment.
Figures
References
- Kumasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1766:1–2.10.1016/j.bbcan.2006.05.003
- Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2007) 28:20–47.10.1210/er.2006-0001
- Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, et al. Clinical significance of insulin-like growth factor-binding protein 3 expression in stage I non-small cell lung cancer. Clin Cancer Res (2002) 8:3796–802.
- Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, et al. High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol (2007) 25(18S):7550.
- Karp DD, Paz-Ares LG, Blakely LJ, Kreisman H, Eisenberg PD, Cohen RB, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-1R) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (2007) 25(18S):7506.
- Langer C, Novello S, Park K, Krazokowski M, Karp DD, Mok T, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol (2014) 32:2059–66.10.1200/JCO.2013.54.4932
- Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti–type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res (2005) 11:2063–73.10.1158/1078-0432.CCR-04-1070
- Gualbert A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients 18 with non–small-cell lung cancer. Clin Lung Cancer (2009) 10(4):273–80.10.3816/CLC.2009.n.038
- Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol (2007) 25(18S):3586.
- Retraction. J Clin Oncol (2012). Available from:
- Hixon ML, Gualberto A, Demers L, Paz-Ares LG, Novello S, Blakely LJ, et al. Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871). J Clin Oncol (2009) 27(No 15S):3539.
- Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 14:6364–70.10.1158/1078-0432.CCR-07-4879
- Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs (2011) 20(5):605–21.10.1517/13543784.2011.558501
- Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 5(7):1676–82.10.1158/1535-7163.MCT-05-0175
- Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël M-J, Barbu V, Fartoux L, Poupon R, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer (2006) 119:2557–66.10.1002/ijc.22221
Source: PubMed